Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

203 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients.
Machiels JP, Gomez-Roca C, Michot JM, Zamarin D, Mitchell T, Catala G, Eberst L, Jacob W, Jegg AM, Cannarile MA, Watson C, Babitzki G, Korski K, Klaman I, Teixeira P, Hoves S, Ries C, Meneses-Lorente G, Michielin F, Christen R, Rüttinger D, Weisser M, Delord JP, Cassier P. Machiels JP, et al. Among authors: michot jm. J Immunother Cancer. 2020 Oct;8(2):e001153. doi: 10.1136/jitc-2020-001153. J Immunother Cancer. 2020. PMID: 33097612 Free PMC article. Clinical Trial.
Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies.
Aftimos P, Rolfo C, Rottey S, Offner F, Bron D, Maerevoet M, Soria JC, Moshir M, Dreier T, Van Rompaey L, Michot JM, Silence K, Hultberg A, Gandini D, de Haard H, Ribrag V, Peeters M, Thibault A, Leupin N, Awada A. Aftimos P, et al. Among authors: michot jm. Clin Cancer Res. 2017 Nov 1;23(21):6411-6420. doi: 10.1158/1078-0432.CCR-17-0613. Epub 2017 Aug 1. Clin Cancer Res. 2017. PMID: 28765328 Clinical Trial.
Post-shingles granulomatous dermatosis related to anti-programmed cell death 1.
Assi T, Danu A, Mateus C, Robert C, Michot JM, Ibrahim T, Lazarovici J, Ghez D, Rossignol J, Dartigues P, Terroir-Cassou-Mounat M, Ribrag V. Assi T, et al. Among authors: michot jm. Immunotherapy. 2019 May;11(7):591-598. doi: 10.2217/imt-2018-0169. Immunotherapy. 2019. PMID: 30943861
Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study.
Manson G, Maria ATJ, Poizeau F, Danlos FX, Kostine M, Brosseau S, Aspeslagh S, Du Rusquec P, Roger M, Pallix-Guyot M, Ruivard M, Dousset L, Grignou L, Psimaras D, Pluvy J, Quéré G, Grados F, Duval F, Bourdain F, Maigne G, Perrin J, Godbert B, Taifas BI, Forestier A, Voisin AL, Martin-Romano P, Baldini C, Marabelle A, Massard C, Honnorat J, Lambotte O, Michot JM. Manson G, et al. Among authors: michot jm. J Immunother Cancer. 2019 Dec 3;7(1):337. doi: 10.1186/s40425-019-0821-8. J Immunother Cancer. 2019. PMID: 31796119 Free PMC article.
Patterns of progression in patients treated for immuno-oncology antibodies combination.
Bernard-Tessier A, Baldini C, Castanon E, Martin P, Champiat S, Hollebecque A, Postel-Vinay S, Varga A, Bahleda R, Gazzah A, Michot JM, Ribrag V, Armand JP, Marabelle A, Soria JC, Massard C, Ammari S. Bernard-Tessier A, et al. Among authors: michot jm. Cancer Immunol Immunother. 2021 Jan;70(1):221-232. doi: 10.1007/s00262-020-02647-z. Epub 2020 Jul 22. Cancer Immunol Immunother. 2021. PMID: 32700090 Free PMC article. Clinical Trial.
Cusatuzumab for treatment of CD70-positive relapsed or refractory cutaneous T-cell lymphoma.
Leupin N, Zinzani PL, Morschhauser F, Dalle S, Maerevoet M, Michot JM, Ribrag V, Offner F, Beylot-Barry M, Moins-Teisserenc H, Zwaenepoel K, de Winne K, Battistella M, Hultberg A, Gandini D, Moshir M, Jacobs J, Delahaye T, Khan A, Zabrocki P, Silence K, van Rompaey L, Borg C, Motta G, Melle F, Calleri A, Pauwels P, de Haard H, Pileri S, Bagot M. Leupin N, et al. Among authors: michot jm. Cancer. 2022 Mar 1;128(5):1004-1014. doi: 10.1002/cncr.34005. Epub 2021 Nov 2. Cancer. 2022. PMID: 34726773 Free article. Clinical Trial.
Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers.
Baldini C, Danlos FX, Varga A, Texier M, Halse H, Mouraud S, Cassard L, Champiat S, Signolle N, Vuagnat P, Martin-Romano P, Michot JM, Bahleda R, Gazzah A, Boselli L, Bredel D, Grivel J, Mohamed-Djalim C, Escriou G, Grynszpan L, Bigorgne A, Rafie S, Abbassi A, Ribrag V, Postel-Vinay S, Hollebecque A, Susini S, Farhane S, Lacroix L, Parpaleix A, Laghouati S, Zitvogel L, Adam J, Chaput N, Soria JC, Massard C, Marabelle A. Baldini C, et al. Among authors: michot jm. J Exp Clin Cancer Res. 2022 Jul 7;41(1):217. doi: 10.1186/s13046-022-02423-0. J Exp Clin Cancer Res. 2022. PMID: 35794623 Free PMC article. Clinical Trial.
Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease.
Danlos FX, Voisin AL, Dyevre V, Michot JM, Routier E, Taillade L, Champiat S, Aspeslagh S, Haroche J, Albiges L, Massard C, Girard N, Dalle S, Besse B, Laghouati S, Soria JC, Mateus C, Robert C, Lanoy E, Marabelle A, Lambotte O. Danlos FX, et al. Among authors: michot jm. Eur J Cancer. 2018 Mar;91:21-29. doi: 10.1016/j.ejca.2017.12.008. Epub 2018 Jan 10. Eur J Cancer. 2018. PMID: 29331748
Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression.
Bernard-Tessier A, Baldini C, Martin P, Champiat S, Hollebecque A, Postel-Vinay S, Varga A, Bahleda R, Gazzah A, Michot JM, Ribrag V, Armand JP, Marabelle A, Soria JC, Massard C. Bernard-Tessier A, et al. Among authors: michot jm. Eur J Cancer. 2018 Sep;101:160-164. doi: 10.1016/j.ejca.2018.06.005. Epub 2018 Jul 30. Eur J Cancer. 2018. PMID: 30071444
203 results